Full text is available at the source.
Abstract
Observational associations suggest that glucagon-like peptide-1 (GLP-1)-based therapy may influence respiratory outcomes in individuals with obesity and asthma.
- Obesity is linked to increased asthma severity.
- GLP-1-based therapy is associated with respiratory outcomes in this population.
- The relationship between GLP-1 therapy and respiratory health may be influenced by treatment selection factors.
Simplified